Related Experiment Video
Updated: Jun 21, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Therapeutic prospect of Syk inhibitors
Paolo Ruzza1, Barbara Biondi, Andrea Calderan
1Institute of Biomolecular Chemistry of CNR, Padova Unit, c/o Dept. Chemical Sciences, University of Padova, via Marzolo 1, Padua, Italy. paolo.ruzza@unipd.it
Background:
The non-receptor spleen tyrosine kinase (Syk; EC 2.7.10.2) is involved in signal transduction in a variety of cell types. In particular, it is a key mediator of immune receptors signaling in host inflammatory cells (B cells, mast cells, macrophages and neutrophils), important for both allergic and antibody-mediated autoimmune diseases. Deregulated Syk kinase activity also allows growth factor-independent proliferation and transforms bone marrow-derived pre-B cells that are able to induce leukemia. Consequently, the development of Syk kinase inhibitors could conceivably treat these disorders and so they have became a major focus in the pharmaceutical and biotech industry.
Objective:
In this review, we analyze the structure and role of Syk kinase, the use of small molecules, interacting with ATP-binding site, as inhibitors of kinase activity and finally the potential of using inhibitors of Syk kinase expression to attenuate pathological conditions.
Conclusion:
Syk kinase inhibition is suggested as a powerful tool for the therapy of different pathologies.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
The JAK-STAT Signaling Pathway
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
